

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 25, 2007

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On April 25, 2007, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for the second fiscal quarter ending March 31, 2007. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

- Revenues. We present revenue growth rates at constant foreign exchange rates. We believe that presenting revenue growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
 - Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, for the second quarter and for the first six months of fiscal year 2006 after excluding the impact of insurance settlements occurring during the period. These settlements caused reported selling and administrative expense to be lower than it otherwise would have been for the period in which they occurred, although these settlements are not considered part of ordinary operations by management. Accordingly, we believe that measures of selling and administrative expense that are adjusted for the effects of these settlements are more indicative of BD’s underlying performance and assist investors in comparing BD’s selling and administrative expense for the period to other periods.
 - Research and Development Expense. We present research and development expense, both alone and as a percentage of revenues, for the first six months of fiscal year 2007 after excluding the impact of the in-process research and development (“R&D”) charge relating to the acquisition of TriPath Imaging, Inc. (“TriPath”). We also present these measures for the second quarter and first six months of fiscal year 2006 after excluding the impact of the in-process R&D charge relating to the acquisition of GeneOhm Sciences Inc. (“GeneOhm”). These noncash charges are not considered by management to be part of ordinary operations and served to increase reported R&D expense for the period in which they were incurred. Management believes that these adjusted measures are more indicative of BD’s R&D activities for the period presented. Management also presents these adjusted measures in order to assist investors in comparing BD’s R&D expense for the period to other periods.
 - Operating Income. We present BD’s operating income, both alone and as a percentage of revenues, for the first six months of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. We also present these measures for the second quarter and first six months of fiscal year 2006 after excluding the impact of insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported operating income for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD’s underlying performance, and also allow investors to better understand BD’s comparative operating performance for the period presented.
 - Income Taxes/Effective Tax Rate. We present income taxes and effective tax rate for the second quarter and first six months of fiscal year 2006 after excluding the impact of insurance settlements. These settlements caused our reported income tax expense and effective tax rate to be higher than they otherwise would have been for the period in which they occurred, although these settlements are not considered part of ordinary operations by management. Management believes that these adjusted measures of income taxes are more indicative of BD’s underlying results, and also allow investors to better understand BD’s comparative income tax expense and tax rate for the period presented.
-

- Income from Continuing Operations. We present BD's income from continuing operations, both alone and as a percentage of revenues, for the first six months of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. We also present BD's income from continuing operations, both alone and as a percentage of revenues, for the second quarter and first six months of fiscal year 2006 after excluding the impact of insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported income from continuing operations for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative income from continuing operations for the period presented.
- Earnings Per Share. We present earnings per share from continuing operations for the first six months of fiscal year 2007 (and projected earnings per share from continuing operations for fiscal year 2007) after excluding the impact of the in-process R&D charge relating to the TriPath acquisition. This charge caused (or will cause) reported earnings per share for the period to be lower than it otherwise would have been, although the charge is not considered by management to be part of ordinary operations. We believe that a measure of earnings per share that is adjusted for the impact of this charge is more indicative of BD's underlying performance and also allows investors to more easily compare BD's results for the period to other periods.

We also present earnings per share from continuing operations for the second quarter of fiscal year 2006, the first six months of fiscal year 2006 and the full 2006 fiscal year after excluding the impact of insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported earnings per share for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of earnings per share are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative performance for the period presented.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated April 25, 2007, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: April 25, 2007

INDEX TO EXHIBITS

**Exhibit
Number**

Description of Exhibits

99.1

Press release dated April 25, 2007, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR SECOND FISCAL QUARTER

- Second-quarter earnings per share from continuing operations increase 12% to 92 cents, excluding specified items
- Raises guidance for full fiscal year 2007 earnings per share from continuing operations to \$3.76 to \$3.80 from \$3.71 to \$3.77, excluding specified items

Franklin Lakes, NJ (April 25, 2007) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.576 billion for the second fiscal quarter ended March 31, 2007, representing an increase of 11 percent over the prior year period. This quarter's growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 3 percentage points of the increase in quarterly revenues.

"We are pleased with the strength of our second quarter results and outlook for fiscal 2007. BD's strategy of providing innovative solutions to global healthcare needs continues to fuel our growth," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Our improving gross margin is providing the necessary resources to invest for the future. The combination of our strong operations, internal investments in research and development and recent acquisitions of GeneOhm and TriPath provides the basis for us to look to the future with confidence."

Analysis of Second Quarter and Six-Month Period of Fiscal Year 2007 and 2006 Earnings

Reported diluted earnings per share from continuing operations were 92 cents for the second quarter of fiscal 2007. The following analysis (Table 1) of diluted earnings per share from continuing operations for the second quarters of fiscal 2007 and 2006 identifies specified items that affect comparability of results between periods. As illustrated, second quarter fiscal 2007 diluted earnings per share from continuing operations increased by 12 percent over comparable second quarter fiscal 2006 diluted earnings per share from continuing operations of 82 cents, which exclude specified items. For the six-month periods, diluted earnings per share from continuing operations of \$1.89 for fiscal 2007, which exclude specified item, increased by 13 percent over comparable fiscal 2006 diluted earnings per share from continuing operations of \$1.67, which exclude specified items.

<u>(Table 1)</u>	<u>Three Months Ended March 31,</u>			<u>Six Months Ended March 31,</u>		
	<u>FY2007</u>	<u>FY2006</u>	<u>% Change</u>	<u>FY2007</u>	<u>FY2006</u>	<u>% Change</u>
Diluted EPS from Continuing Operations:	\$ 0.92	\$ 0.63	46%	\$ 1.44	\$ 1.51	-5%
<u>Specified Items:</u>						
In-Process Research and Development Charge ⁽¹⁾	—	0.21		0.45	0.21	
Insurance Settlement ⁽²⁾	—	(0.02)		—	(0.04)	
Rounding	—	—		—	(0.01)	
	—	0.19		0.45	0.16	
Diluted EPS from Continuing Operations						
Excluding Specified Items:	<u>\$ 0.92</u>	<u>\$ 0.82</u>	<u>12%</u>	<u>\$ 1.89</u>	<u>\$ 1.67</u>	<u>13%</u>

⁽¹⁾ Represents the effect on diluted earnings per share from continuing operations of the in-process research and development (“IPR&D”) charges recorded in the second quarter of fiscal 2006 and the first quarter of fiscal 2007 related to the GeneOhm and TriPath acquisitions, respectively.

⁽²⁾ Represents the effect on diluted earnings per share from continuing operations of 2 cents in each of the first and second quarter of fiscal 2006 related to proceeds received from insurance settlements associated with the Company’s previously owned latex glove business.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$844 million, representing an increase of 10 percent from the prior year period. For the six-month period ended March 31, 2007, the BD Medical segment reported 10 percent revenue growth. Strong sales in the Pharmaceutical Systems unit continued to significantly contribute to the growth of the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$473 million, representing an increase of 11 percent from the prior year’s quarter, despite continued slow sales of flu testing products. This growth includes \$27 million of revenues from TriPath, which was acquired at the end of the first quarter of fiscal 2007. The Preanalytical Systems unit of the segment reported revenue growth of 8 percent. Second quarter revenues in the Diagnostic Systems unit of the segment increased 15 percent, again including revenues from the TriPath acquisition. For the six-month period ended March 31, 2007, the BD Diagnostics segment reported 7 percent revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were \$259 million, representing an increase of 13 percent from the prior year’s quarter. Flow cytometry instrument and reagent sales, as well as sales of advanced bioprocessing products, contributed to growth. For the six-month period ended March 31, 2007, the BD Biosciences segment reported 12 percent revenue growth, resulting from continued strong sales of those same products.

Geographic Results

Second quarter revenues in the U.S. were \$754 million, representing an increase of 11 percent over the prior year period and include \$27 million of revenues from TriPath. Revenues outside the U.S. were \$822 million, representing an increase of 10 percent over the prior year period. Approximately 5 percentage points of the increase resulted from the favorable impact of foreign currency translation.

For the six-month period ended March 31, 2007, revenues in the U.S. were \$1.475 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were \$1.603 billion, representing an increase of 8 percent over the prior year period. Approximately 4 percentage points of the increase relate to the favorable impact from foreign currency translation.

Fiscal 2007 Outlook for Full Year

The following analysis (Table 2) of estimated diluted earnings per share from continuing operations for the full fiscal year identifies specified items that affect the comparability of results between periods. As illustrated, the Company estimates that diluted earnings per share from continuing operations, excluding specified item, for the full fiscal year 2007 will be in the \$3.76 to \$3.80 range, representing an increase of approximately 13 to 14 percent over diluted earnings per share from continuing operations, excluding specified items, of \$3.34 for the fiscal year 2006.

(Table 2)

	Twelve Months Ended		
	September 30,		
	FY2007	FY2006	% Change
	(Estimated)		
Diluted EPS from Continuing Operations:	\$ 3.31-\$3.35	\$ 3.18	4 %-5%
Specified Items:			
In-Process Research and Development Charge ⁽¹⁾	0.45	0.21	
Insurance Settlements ⁽²⁾	—	(0.04)	
Rounding	—	(0.01)	
	<u>0.45</u>	<u>0.16</u>	
Diluted EPS from Continuing Operations			
Excluding Specified Items:	<u>\$ 3.76-\$3.80</u>	<u>\$ 3.34</u>	<u>13 %-14%</u>

(1) Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the first quarter of fiscal 2007 and the second quarter of fiscal 2006 related to the TriPath and GeneOhm acquisitions, respectively.

(2) Represents the effect on estimated diluted earnings per share from continuing operations of 2 cents in each of the first and second quarter of fiscal 2006 related to proceeds received from insurance settlements associated with the Company's previously owned latex glove business.

Conference Call Information

A conference call regarding BD's second fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Wednesday, April 25, 2007. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-866-373-9238 (domestic) and 1-203-369-0284 (international) through the close of business on Wednesday, May 2, 2007.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2007 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Three Months Ended March 31,		
	2007	2006	% Change
REVENUES	\$ 1,575,922	\$ 1,424,209	10.7
Cost of products sold	764,540	698,766	9.4
Selling and administrative	406,631	346,322	17.4
Research and development	86,687	127,715	(32.1)
TOTAL OPERATING COSTS AND EXPENSES	1,257,858	1,172,803	7.3
OPERATING INCOME	318,064	251,406	26.5
Interest expense	(11,686)	(19,805)	(41.0)
Interest income	9,086	16,991	(46.5)
Other expense, net	5,872	(451)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	321,336	248,141	29.5
Income tax provision	85,797	84,683	1.3
INCOME FROM CONTINUING OPERATIONS	235,539	163,458	44.1
INCOME/(LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX OF PROVISION / (BENEFIT) OF \$4,222 AND \$(5,713), RESPECTIVELY	6,994	(9,390)	NM
NET INCOME	\$ 242,533	\$ 154,068	57.4
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.96	\$ 0.66	45.5
Income/(loss) from discontinued operations	\$ 0.03	\$ (0.04)	NM
Net income	\$ 0.99	\$ 0.62	59.7
Diluted:			
Income from continuing operations	\$ 0.92	\$ 0.63	46.0
Income/(loss) from discontinued operations	\$ 0.03	\$ (0.04)	NM
Net income (1)	\$ 0.95	\$ 0.60	58.3
AVERAGE SHARES OUTSTANDING			
Basic	245,418	248,088	
Diluted	254,740	258,299	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended March 31,
(Unaudited; Amounts in thousands, except per-share data)

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm IPR&D (2)	Excluding Items
Selling and administrative as a % of revenues	\$ 346,322 24.3%	\$ 10,000	\$ —	\$ 356,322 25.0%
Research and development as a % of revenues	127,715 9.0%	—	(53,300)	74,415 5.2%
Operating Income as a % of revenues	251,406 17.7%	(10,000)	53,300	294,706 20.7%
Income taxes effective tax rate	84,683 34.1%	(3,800)	—	80,883 27.8%
Income from continuing operations as a % of revenues	163,458 11.5%	(6,200)	53,300	210,558 14.8%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 0.63	\$ (0.02)	\$ 0.21	\$ 0.82

(1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Six Months Ended March 31,		
	2007	2006	% Change
REVENUES	\$ 3,077,449	\$ 2,818,054	9.2
Cost of products sold	1,473,474	1,364,712	8.0
Selling and administrative	790,715	695,349	13.7
Research and development	281,366	196,074	43.5
TOTAL OPERATING COSTS AND EXPENSES	2,545,555	2,256,135	12.8
OPERATING INCOME	531,894	561,919	(5.3)
Interest expense	(24,555)	(36,565)	(32.8)
Interest income	25,200	31,662	(20.4)
Other expense, net	3,505	(1,614)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	536,044	555,402	(3.5)
Income tax provision	169,454	168,242	0.7
INCOME FROM CONTINUING OPERATIONS	366,590	387,160	(5.3)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION / (BENEFIT) OF \$11,362 AND \$(9,262), RESPECTIVELY	18,822	(15,232)	NM
NET INCOME	\$ 385,412	\$ 371,928	3.6
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.49	\$ 1.56	(4.5)
Income (loss) from discontinued operations	\$ 0.08	\$ (0.06)	NM
Net income	\$ 1.57	\$ 1.50	4.7
Diluted:			
Income from continuing operations	\$ 1.44	\$ 1.51	(4.6)
Income (loss) from discontinued operations	\$ 0.07	\$ (0.06)	NM
Net income	\$ 1.51	\$ 1.45	4.1
AVERAGE SHARES OUTSTANDING			
Basic	245,484	248,067	
Diluted	255,178	257,145	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Six Months Ended March 31,
(Unaudited; Amounts in thousands, except per-share data)

	2007		
	As Reported	TriPath IPR&D (1)	Excluding Charges
Research and development as a % of revenues	\$ 281,366 9.1%	\$ (114,739)	\$ 166,627 5.4%
Operating Income as a % of revenues	531,894 17.3%	114,739	646,633 21.0%
Income from continuing operations as a % of revenues	536,044 17.4%	114,739	650,783 21.1%
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 1.44	\$ 0.45	\$ 1.89

(1) Represents the IPR&D charge related to the TriPath acquisition.

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm IPR&D (2)	Excluding Items
Selling and administrative as a % of revenues	\$ 695,349 24.7%	\$ 17,000	\$ —	\$ 712,349 25.3%
Research and development as a % of revenues	196,074 7.0%	—	(53,300)	142,774 5.1%
Operating Income as a % of revenues	561,919 19.9%	(17,000)	53,300	598,219 21.2%
Income taxes effective tax rate	168,242 30.3%	(6,460)	—	161,782 27.3%
Income from continuing operations as a % of revenues	387,160 13.7%	(10,540)	53,300	429,920 15.3%
<u>Diluted earnings per share</u>				
Income from continuing operations (3)	\$ 1.51	\$ (0.04)	\$ 0.21	\$ 1.67

(1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the IPR&D charge related to the GeneOhm acquisition.

(3) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Three Months Ended March 31,		
	2007	2006	% Change
<u>BD MEDICAL</u>			
United States	\$ 378,789	\$ 350,061	8.2
International	465,355	420,169	10.8
TOTAL	\$ 844,144	\$ 770,230	9.6
<u>BD DIAGNOSTICS</u>			
United States	\$ 265,800	\$ 228,569	16.3
International	207,430	196,598	5.5
TOTAL	\$ 473,230	\$ 425,167	11.3
<u>BD BIOSCIENCES</u>			
United States	\$ 109,429	\$ 99,659	9.8
International	149,119	129,153	15.5
TOTAL	\$ 258,548	\$ 228,812	13.0
<u>TOTAL REVENUES</u>			
United States	\$ 754,018	\$ 678,289	11.2
International	821,904	745,920	10.2
TOTAL	\$ 1,575,922	\$ 1,424,209	10.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Six Months Ended March 31,		
	2007	2006	% Change
<u>BD MEDICAL</u>			
United States	\$ 760,596	\$ 697,731	9.0
International	909,795	822,983	10.5
TOTAL	\$ 1,670,391	\$ 1,520,714	9.8
<u>BD DIAGNOSTICS</u>			
United States	\$ 508,699	\$ 453,300	12.2
International	406,932	405,985	0.2
TOTAL	\$ 915,631	\$ 859,285	6.6
<u>BD BIOSCIENCES</u>			
United States	\$ 205,349	\$ 189,330	8.5
International	286,078	248,725	15.0
TOTAL	\$ 491,427	\$ 438,055	12.2
<u>TOTAL REVENUES</u>			
United States	\$ 1,474,644	\$ 1,340,361	10.0
International	1,602,805	1,477,693	8.5
TOTAL	\$ 3,077,449	\$ 2,818,054	9.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31,
(Unaudited; Amounts in thousands)

	United States		
	2007	2006	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 230,881	\$ 220,050	4.9
Diabetes Care	97,647	92,471	5.6
Pharmaceutical Systems	44,370	32,028	38.5
Ophthalmic Systems	5,891	5,512	6.9
TOTAL	\$ 378,789	\$ 350,061	8.2
BD DIAGNOSTICS			
Preanalytical Systems	\$ 131,937	\$ 125,412	5.2
Diagnostic Systems	133,863	103,157	29.8
TOTAL	\$ 265,800	\$ 228,569	16.3
BD BIOSCIENCES			
Discovery Labware	\$ 37,710	\$ 33,106	13.9
Immunocytometry Systems	51,546	46,226	11.5
Pharmingen	20,173	20,327	(0.8)
TOTAL	\$ 109,429	\$ 99,659	9.8
TOTAL UNITED STATES	\$ 754,018	\$ 678,289	11.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

			International		
	2007	2006	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 216,459	\$ 204,531	5.8	1.3	4.5
Diabetes Care	73,544	70,715	4.0	(0.8)	4.8
Pharmaceutical Systems	164,442	135,081	21.7	13.3	8.4
Ophthalmic Systems	10,910	9,842	10.9	3.4	7.5
TOTAL	\$ 465,355	\$ 420,169	10.8	4.9	5.9
BD DIAGNOSTICS					
Preanalytical Systems	\$ 112,809	\$ 101,449	11.2	5.4	5.8
Diagnostic Systems	94,621	95,149	(0.6)	(4.3)	3.7
TOTAL	\$ 207,430	\$ 196,598	5.5	0.7	4.8
BD BIOSCIENCES					
Discovery Labware	\$ 32,625	\$ 30,535	6.8	2.8	4.0
Immunocytometry Systems	93,056	77,348	20.3	14.6	5.7
Pharmingen	23,438	21,270	10.2	5.3	4.9
TOTAL	\$ 149,119	\$ 129,153	15.5	10.3	5.2
TOTAL INTERNATIONAL	\$ 821,904	\$ 745,920	10.2	4.7	5.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	2007	2006	Total		
			% Change Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 447,340	\$ 424,581	5.4	3.2	2.2
Diabetes Care	171,191	163,186	4.9	2.8	2.1
Pharmaceutical Systems	208,812	167,109	25.0	18.2	6.8
Ophthalmic Systems	16,801	15,354	9.4	4.6	4.8
TOTAL	\$ 844,144	\$ 770,230	9.6	6.4	3.2
BD DIAGNOSTICS					
Preanalytical Systems	\$ 244,746	\$ 226,861	7.9	5.3	2.6
Diagnostic Systems	228,484	198,306	15.2	13.4	1.8
TOTAL	\$ 473,230	\$ 425,167	11.3	9.1	2.2
BD BIOSCIENCES					
Discovery Labware	\$ 70,335	\$ 63,641	10.5	8.6	1.9
Immunocytometry Systems	144,602	123,574	17.0	13.5	3.5
Pharming	43,611	41,597	4.8	2.3	2.5
TOTAL	\$ 258,548	\$ 228,812	13.0	10.1	2.9
TOTAL REVENUES	\$ 1,575,922	\$ 1,424,209	10.7	7.8	2.9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31,
(Unaudited; Amounts in thousands)

	United States		
	2007	2006	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 473,183	\$ 442,316	7.0
Diabetes Care	188,139	183,959	2.3
Pharmaceutical Systems	87,269	60,428	44.4
Ophthalmic Systems	12,005	11,028	8.9
TOTAL	\$ 760,596	\$ 697,731	9.0
BD DIAGNOSTICS			
Preanalytical Systems	\$ 263,640	\$ 248,201	6.2
Diagnostic Systems	245,059	205,099	19.5
TOTAL	\$ 508,699	\$ 453,300	12.2
BD BIOSCIENCES			
Discovery Labware	\$ 71,798	\$ 65,163	10.2
Immunocytometry Systems	95,450	86,663	10.1
Pharmingen	38,101	37,504	1.6
TOTAL	\$ 205,349	\$ 189,330	8.5
TOTAL UNITED STATES	\$ 1,474,644	\$ 1,340,361	10.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	2007	2006	International		
			% Change Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 441,909	\$ 410,428	7.7	3.8	3.9
Diabetes Care	151,738	142,707	6.3	2.2	4.1
Pharmaceutical Systems	294,483	250,444	17.6	10.8	6.8
Ophthalmic Systems	21,665	19,404	11.7	5.5	6.2
TOTAL	\$ 909,795	\$ 822,983	10.5	5.7	4.8
BD DIAGNOSTICS					
Preanalytical Systems	\$ 221,179	\$ 200,823	10.1	5.1	5.0
Diagnostic Systems	185,753	205,162	(9.5)	(12.3)	2.8
TOTAL	\$ 406,932	\$ 405,985	0.2	(3.7)	3.9
BD BIOSCIENCES					
Discovery Labware	\$ 62,426	\$ 57,923	7.8	4.2	3.6
Immunocytometry Systems	178,752	149,763	19.4	14.5	4.9
Pharminggen	44,900	41,039	9.4	5.3	4.1
TOTAL	\$ 286,078	\$ 248,725	15.0	10.6	4.4
TOTAL INTERNATIONAL	\$ 1,602,805	\$ 1,477,693	8.5	3.9	4.6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

	2007	2006	Total		
			% Change Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 915,092	\$ 852,744	7.3	5.4	1.9
Diabetes Care	339,877	326,666	4.0	2.2	1.8
Pharmaceutical Systems	381,752	310,872	22.8	17.4	5.4
Ophthalmic Systems	33,670	30,432	10.6	6.7	3.9
TOTAL	\$ 1,670,391	\$ 1,520,714	9.8	7.2	2.6
BD DIAGNOSTICS					
Preanalytical Systems	\$ 484,819	\$ 449,024	8.0	5.7	2.3
Diagnostic Systems	430,812	410,261	5.0	3.6	1.4
TOTAL	\$ 915,631	\$ 859,285	6.6	4.7	1.9
BD BIOSCIENCES					
Discovery Labware	\$ 134,224	\$ 123,086	9.0	7.3	1.7
Immunocytometry Systems	274,202	236,426	16.0	12.9	3.1
Pharmingen	83,001	78,543	5.7	3.5	2.2
TOTAL	\$ 491,427	\$ 438,055	12.2	9.7	2.5
TOTAL REVENUES	\$ 3,077,449	\$ 2,818,054	9.2	6.8	2.4

BECTON DICKINSON AND COMPANY
SUMMARY OF ANNUAL SELECTED FINANCIAL DATA
Revised for Blood Glucose Monitoring Discontinued Operations
(Unaudited; Amounts in thousands, except per share data)

	2006	2005	2004	2003	2002	2001
OPERATIONS						
Revenues	\$ 5,738,017	\$ 5,340,833	\$ 4,893,915	\$ 4,449,126	\$ 3,960,359	\$ 3,667,575
Research and development	355,172	267,664	230,768	218,524	201,075	193,753
Operating income	1,141,414	1,063,845	878,201	800,841	689,085	645,882
Income from continuing operations before income taxes	1,125,902	1,037,529	843,802	761,567	642,076	548,576 (1)
Income tax provision	310,792	325,009	204,852	182,058	153,673	139,278
Diluted earnings per share from continuing operations	\$ 3.18	\$ 2.73	\$ 2.43	\$ 2.20	\$ 1.82	\$ 1.52
FINANCIAL RELATIONSHIPS						
Gross profit margin	51.3%	50.9%	50.5%	48.9%	48.3%	48.7%
Return on revenues (4)	14.2%	13.3%	13.1%	13.0%	12.3%	12.2% (3)
Return on total assets (2)(4)	18.4%	18.4%	15.7%	15.2%	13.9%	13.9%
Return on equity (4)	22.9%	22.4%	21.4%	21.6%	20.3%	20.7% (3)
ADDITIONAL DATA						
Depreciation and amortization	\$ 386,995	\$ 382,669	\$ 351,149	\$ 332,815	\$ 294,652	\$ 291,993
Capital expenditures	457,067	315,840	260,473	253,007	253,491	364,076

(1) Includes cumulative effect of accounting changes of \$36.8 million (\$.14 per basic and diluted share).

(2) Earnings before interest expense, taxes and cumulative effect of accounting changes as a percent of average assets.

(3) Excludes the cumulative effect of accounting changes.

(4) Excludes discontinued operations.